The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.

Inclusion Criteria:

• Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule

Exclusion Criteria:

• Pregnancy or breastfeeding
• Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
• Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
• Patients with a physical or psychological condition that would impair study participation.
• The patient is judged unsuitable for study participation by the Investigator for any other reason

The study team will seek and IRB determination prior to any secondary uses of data in the future for research related to qDSA. A change of protocol will be submitted to the IRB to report any sharing of data to institutions other than the sponsor.